Program
delgocitinib
Also written as “Delgocitinib cream”, “Delgocitinib” and “LEO 124249”.
Its studies are mostly in Eczema · Psoriasis · Dermatitis, Atopic · Alopecia Areata · Lichen Sclerosus et Atrophicus, led by LEO Pharma.
Furthest: phase 3, since Apr 29, 202121 company-led studies, 2 open or runningNext primary completion: Jun 4, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharma | 212 open or running | phase 3since Apr 29, 2021 | Sep 25, 2015 | Jun 4, 2027phase 2 · NCT07013201 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Sep 25, 2015.
- May 20, 2019Phase 2 study in Lupus Erythematosus, DiscoidNCT03958955 · 27 enrolled · United States, Denmark, France and more
- Apr 22, 2020Phase 1 study in HealthyNCT04361136 · 35 enrolled · Germany
- Mar 18, 2021Phase 1 study in HealthyNCT04807751 · 60 enrolled · Germany
- Apr 29, 20212 phase 3 studies in Chronic Hand EczemaNCT04872101, NCT04871711
- Jun 29, 2021Phase 3 study in Chronic Hand EczemaNCT04949841 · 801 enrolled · Belgium, Canada, Denmark and more
- Jul 5, 2021Early phase 1 study in HealthyNCT05050279 · 40 enrolled · United Kingdom
- Feb 18, 2022Phase 3 study in Chronic Hand EczemaNCT05259722 · 513 enrolled · Austria, Canada, France and more
- Apr 11, 2022Phase 2 study in Frontal Fibrosing AlopeciaNCT05332366 · 35 enrolled · United States
- Apr 27, 2022Phase 3 study in Chronic Hand EczemaNCT05355818 · 98 enrolled · Australia, Belgium, Canada and more
- Jul 18, 2022Phase 1 study in Chronic Hand EczemaNCT05486117 · 15 enrolled · Germany
- Aug 16, 2023Phase 3 study in Skin DiseasesNCT06004050 · 362 enrolled · China
- Jun 2, 2025Phase 2 study in PsoriasisNCT07013201 · 135 planned · United States, Canada, Germany and more
- Jan 9, 2026Phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588 · 652 planned · United States, Canada, United Kingdom
- Nov 9, 2026Primary completion moved from 2026-12-14 to 2027-06-04Date moved laterphase 2 · +6 months · NCT07013201
Ahead
- Jun 4, 2027Primary completion: phase 2 study in PsoriasisNCT07013201
- Mar 10, 2028Primary completion: phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588
TargetBeta
“Janus Kinase (JAK) inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07335588Lichen Sclerosus et Atrophicus · United States, Canada, United Kingdom | 3 | Recruiting | Mar 10, 2028 | 652 |
| NCT07013201Psoriasis · United States, Canada, Germany and more | 2 | Recruiting | Jun 4, 2027 | 135 |
| NCT06004050Skin Diseases · China | 3 | Completed | Dec 16, 2024 | 362 |
| NCT05486117Chronic Hand Eczema · Germany | 1 | Completed | Nov 22, 2022 | 15 |
| NCT05355818Chronic Hand Eczema · Australia, Belgium, Canada and more | 3 | Completed | Dec 5, 2024 | 98 |
| NCT05332366Frontal Fibrosing Alopecia · United States | 2 | Completed | Feb 13, 2023 | 35 |
| NCT05259722Chronic Hand Eczema · Austria, Canada, France and more | 3 | Completed | Nov 8, 2023 | 513 |
| NCT05050279Healthy · United Kingdom | Early 1 | Completed | Jan 4, 2022 | 40 |
| NCT04949841Chronic Hand Eczema · Belgium, Canada, Denmark and more | 3 | Completed | Sep 18, 2023 | 801 |
| NCT04872101Chronic Hand Eczema · Belgium, Canada, Denmark and more | 3 | Completed | Dec 27, 2022 | 473 |
| NCT04871711Chronic Hand Eczema · Canada, France, Germany and more | 3 | Completed | Oct 31, 2022 | 487 |
| NCT04807751Healthy · Germany | 1 | Completed | Jul 30, 2021 | 60 |
| NCT04361136Healthy · Germany | 1 | Completed | May 30, 2020 | 35 |
| NCT03958955Lupus Erythematosus, Discoid · United States, Denmark, France and more | 2 | Terminated | Apr 15, 2020 | 27 |
| NCT03826901Dermatitis, Atopic · United States, Canada | 1 | Completed | Oct 29, 2021 | 46 |
| NCT03725722Dermatitis, Atopic · United States, Australia, Canada | 2 | Completed | May 19, 2020 | 251 |
| NCT03683719Chronic Hand Eczema · United States, Denmark, Germany | 2 | Completed | Mar 6, 2020 | 258 |
| NCT03325296Alopecia Areata · Denmark | 2 | Terminated | May 16, 2018 | 13 |
| NCT02695940Inverse Psoriasis · Germany | 2 | Completed | Sep 2016 | 69 |
| NCT02664805Chronic Hand Eczema · Germany | 2 | Completed | Jul 2016 | 91 |
| NCT02561585Alopecia Areata · United States | 2 | Completed | Dec 2016 | 40 |
How it is read
Names in the registry
- “Delgocitinib cream”, 9 entries
- “Delgocitinib”, 6 entries
- “LEO 124249”, 2 entries
- “LEO 124249 ointment”, 1 entry
- “Delgocitinib capsule”, 1 entry
Conditions, from the studies’ own filings
- Eczema, 9 studies
- Psoriasis, 2 studies
- Dermatitis, Atopic, 2 studies
- Alopecia Areata, 2 studies
- Lichen Sclerosus et Atrophicus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.